Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (June 2025)
30 slides from Rhythm Biosciences's investor presentation, Jun 19, 2025
Slide 1: An Overview of Genetype
For personal use only An Overview of Genetype ERIKA SPAETH, PhD SCIENTIFIC/CLINICAL AFFAIRS
Slide 2: About Rhythm Biosciences
About Rhythm Biosciences We are committed to Early detection of cancer gives individuals the best possible opportunity For personal use only for favorable treatment outcomes. saving lives through the evaluation of cancer risk Addressing large under-served global markets worth >USD$50bn and heavily s
Slide 3: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY For personal use only ASX Code RHY 2 Share Price (17th June 2025) $0.060 1.5 Shares on Issue 283,597M 1 Unlisted & Listed Options 53.4M Market Capitalisation $17.61M 0.5 Cash in Bank (31 March 2025) $2.3M 0 Top 20 Shareholders 43.3% 3
Slide 4: When diagnosed early, cancer can be successfully treated
When diagnosed early, cancer can be successfully treated Disease stage for colorectal cancer diagnosis is the key predictor of survival Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed in: For personal use only Missed detection of early-stage CRC results in poor surviva
Slide 5: Detecting cancer earlier and maintaining wellness
Detecting cancer earlier and maintaining wellness The power of the combination of the Rhythm capabilities and portfolio For personal use only Y N E R U O J Risk Assessment Disease Screening MONITORING AND MINIMAL RESIDUAL T RISK ASSESSMENT DISEASE DETECTION Determination Minimally-invasive detection
Slide 6: Cancer screening is critical to managing cancer burden
Cancer screening is critical to managing cancer burden Detection of cancer as early-stage disease leads to better outcomes For personal use only Adults that are non-compliant screeners 35 - 57% 40% of adults will Rates are increasing in adults under 50 get cancer 25% https://www.cancer.org/research/
Slide 7: Current Screening programs
Current Screening programs The standard of care varies in each geography For personal use only One Size Fits All Hereditary (BRCA1) Family clusters Breast Colorectal Prostate • Start at • Start at 45 • Start at 55 40 or 45 • FIT, • PSA • Mammogram Cologuard, • Frequency/ How do we • Biennial colonos
Slide 8: Cancer is unique to each individual
Cancer is unique to each individual Detection of disease needs to reflect this uniqueness Improve the current standard of care For personal use only from one-size-fits-all screening Personalised screening approaches • Precisely identify who is at risk • Provide tailored risk-reduction options 7 gene
Slide 9: Risk Assessment is the Gateway to Precision Diagnostics
Risk Assessment is the Gateway to Precision Diagnostics The first step to employing personalised screening approaches For personal use only Risk Personalised Prognostic Screening Diagnosis Recurrence assessment treatment response WHAT? WHY? HOW? Predicting a person’s To provide more Validated Assess
Slide 10: geneTypeTM sets the stage for personalised screening options
geneTypeTM sets the stage for personalised screening options Risk assessment allows us to move away from a one-size-fits all screening approach For personal use only RISK RISK TAILORED ASSESSMENT STRATIFICATION SCREENING Intensified screening Medication, surgery Reduced intensity/ alternative screen
Slide 11: Our understanding of the range of risk factors has advanced
Our understanding of the range of risk factors has advanced Each individual’s risk is a factor of multiple variables Scientists can assign VALUEs to risk factors: For personal use only • Family history • Low BMI • High BMI • Cholesterol levels • Blood pressure • Number of live births • Smoking habit
Slide 12: Traditional Risk Assessment vs geneTypeTM
Traditional Risk Assessment Easy-to-identify risk factors For personal use only geneTypeTM Looks at the bigger Genetic Risk picture of risk Polygenic risk score 11 geneType Population Risk Assessment
Slide 13: geneTypeTM is different from other genetic testing
geneTypeTM is different from other genetic testing Genetype detects many common low penetrance genetic variants vs. individual mutations. For personal use only BRCA1/2 • 1 mutation • Very high risk • Rare in the population (0.2-1%) • Sonic, Healius, LabCorp, Myriad geneTypeTM • Many risk factors: ge
Slide 14: geneTypeTM risk assessment
geneTypeTM risk assessment Disease risk prediction is strongest when combining multiple risk factors For personal use only % Chance of developing disease 13 geneType Population Risk Assessment
Slide 15: For personal use only
For personal use only 14 geneType Population Risk Assessment
Slide 16: Inherent risk: We are all born with a polygenic risk profile
Inherent risk: We are all born with a polygenic risk profile Understanding where a patient sits on the spectrum of risk unlocks new opportunities for precision screening and early intervention For personal use only LOW HIGH PATIENT ‘BASELINE’ RISK OF DISEASE Spaeth E. Chapter 2 - Polygenic risk scor
Slide 17: The future of personalised medicine
The future of personalised medicine For personal use only Personalised healthcare Risk assessment © Rhythm Biosciences 2025 16 geneType Population Risk Assessment
Slide 18: geneTypeTM development
geneTypeTM development Creating a risk assessment that contains the fewest, but most impactful risk factors MAJOR CONSIDERATIONS THOUSANDS OF ADULTS WITHOUT THE DISEASE For personal use only • Improve current binary risk (standard of care) • Limit stress to healthcare provider (ease of implementatio
Slide 19: geneTypeTM vs Gold Standard
geneTypeTM vs Gold Standard Test portfolio consists of diseases that performed better than a current clinical standard tool geneTypeTM Disease risk assessment For personal use only Breast1,2 Outperforms Ovarian3 Prostate4 Across the following statistical metrics: Colorectal5,6 ✓ Discrimination ✓ Cal
Slide 20: geneTypeTM risk stratification supports screening and prevention strategies
geneTypeTM risk stratification supports screening and prevention strategies For personal use only Complementing existing screening pathways • Age of entry • Frequency • Modality RISK RISK TAILORED ASSESSMENT STRATIFICATION SCREENING Novel screening technologies Intensified screening, • Single/Multi
Slide 21: Market entry: risk stratification across the healthcare ecosystem
Market entry: risk stratification across the healthcare ecosystem From general practice to specialty care, and from private payors to public health programs—risk stratification enables targeted, value-driven decision-making at every level For personal use only Applications • Applications • Individua
Slide 22: geneTypeTM performance has a material and affordable impact
geneTypeTM performance has a material and affordable impact Breast cancer risk assessment on a population basis and health economics For personal use only Breast Cancer Risk • Cases diagnosed annually (incidence) = 20,640 • Individuals living with disease (prevalence) = 79,720 Economics of Risk Asse
Slide 23: geneTypeTM customer segment summary
geneTypeTM customer segment summary Three distinct customer segments where geneTypeTM would add significant value For personal use only Worried well – 1 Active Risk Assessors – 2 At Higher Risk – 3 Proactive Preventers Actively engaged in assessment Seeking more information Encounter a reason to bel
Slide 24: Rhythm is targeting a significant global market
Rhythm is targeting a significant global market A global market of >0.5bn individuals potentially served by the Rhythm product platform. Genomic Platform: geneTypeTM Proteomic Platform: ColoSTAT® & Lung Cancer Screening For personal use only Unscreened high risk for Unscreened CRC Healthy CRC cancer
Slide 25: There are multiple emerging drivers of geneTypeTM adoption
There are multiple emerging drivers of geneTypeTM adoption Rhythm is well positioned to participate in a major change in clinical practice Impact on For personal use only Major Driver geneTypeTM adoption Clinical Trials: large cohorts BARCODE11, WISDOM2 Efficacy and validation Implementation Studies
Slide 26: Ordering geneTypeTM in Australia using an HCP
Ordering geneTypeTM in Australia using an HCP The ordering options are continuously expanding For personal use only 25
Slide 27: Our combined platforms supports a highly comprehensive approach to cancer diagnostics
Our combined platforms supports a highly comprehensive approach to cancer diagnostics The potential RHY product portfolio addresses a huge total available market For personal use only Y N E R U O J T MONITORING AND RISK MINIMAL RESIDUAL N ASSESSMENT DISEASE DETECTION E Risk Assessment • • • • • • •
Slide 28: Upcoming value inflection points
Upcoming value inflection points For personal use only PRODUCT ITEM DESCRIPTION COMPLETION DATE ColoSTAT® Kit Validation Ready Kit Verification completion, production kits ready Q2 CY 2025 ColoSTAT® Final clinical validation Evaluation of final system Q3 CY 2025 geneTypeTM strategic geneTypeTM Estab
Slide 29: Rhythm Bioscience: An attractive investment opportunity
Rhythm Bioscience: An attractive investment opportunity For personal use only Overview Growth Reasons to Invest Rhythm’s mission is to 1. Multi-product portfolio detect cancer earlier and Rhythm is solving an reduce the burden of important clinical and 2. Addressing a significant TAM cancer. We are
Slide 30: Thank you!
For personal use only Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Investor Presentation (June 2025) on 6ix